Antimicrobial Susceptibility Testing Market By Product, By Method, By Type, By Application, By End User and By Region: Industry Analysis, Market Share, Revenue Opportunity, Competitive Analysis Historical Data from 2018-2024 and Forecast 2025-2033
According to FutureWise analysis, the European Antimicrobial Susceptibility Testing market in 2025 is US$4.67 billion and is expected to reach US$7.15 billion by 2033, at a CAGR of 5.47%. The European Antimicrobial Susceptibility Testing (AST) market is experiencing significant growth due to the increasing prevalence of antimicrobial resistance (AMR) and the rising demand for rapid and accurate diagnostic tools. This growth is further supported by the growing adoption of automated and molecular-based AST technologies, as well as government initiatives that strengthen infection control measures. Additionally, rising healthcare spending and a focus on personalized medicine are expected to create substantial opportunities for key players in the region. Concerns about antimicrobial resistance and the demand for quick diagnostic techniques in healthcare settings are driving this growth. Technological advancements, along with government initiatives that promote antimicrobial stewardship, are also contributing to market expansion. Antimicrobial susceptibility testing (AST) is a laboratory technique used to assess the effectiveness of antibiotics and other antimicrobial agents against specific microorganisms. This testing is crucial because it provides essential information to guide the selection of appropriate antimicrobial therapy for bacterial, fungal, and viral infections. AST involves exposing the microorganism to various concentrations of antimicrobial agents in vitro and determining the minimum inhibitory concentration (MIC) needed to inhibit or kill the organism. The MIC is defined as the lowest concentration of an antimicrobial agent that can prevent the growth of the microorganism.
FutureWise Market Research has instantiated a report that provides an intricate analysis of Antimicrobial Susceptibility Testing Market trends that shall affect the overall market growth.

Request a Free Sample @
https://www.futurewiseresearch.com/contact.aspx?rpt=7885&type=requestsample

By Product
• Automated Laboratory Instruments
• Manual Antimicrobial Susceptibility Testing Products
o Susceptibility Testing Disks
o MIC Strips
o Susceptibility Plates
• Culture and Growth Media
• Consumables

By Method
• Dilution
• Disk Diffusion
• ETEST
• Automated Antimicrobial Susceptibility Testing
• Genotypic Methods

By Type
• Antibacterial Testing
• Antifungal Testing
• Antiparasitic Testing
• Other Susceptibility Testing

By Application
• Clinical Diagnostics
• Drug Discovery and Development
• Epidemiology
• Other Applications

By End User
• Diagnostic Centers and Hospitals
• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Research and Academic Institutes
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa
Competitive Landscape in Antimicrobial Susceptibility Testing Market:
• BioMérieux
• BD
• Danaher
• Thermo Fisher
• Bio-Rad Laboratories
• Hi-Media
• Merlin
• Liofilchem
• Accelerate
• Alifax
• Creative Diagnostics
• Merck Group
• Synbiosis
• Bioanalyse
• Zhuhai DL Biotech.
Recent developments by key players in the Antimicrobial Susceptibility Testing Market:
BioMérieux
• VITEK REVEAL has been introduced as an innovative rapid phenotypic antimicrobial susceptibility testing (AST) system, specifically designed for positive blood cultures, providing results in approximately 3 to 6 hours.
• Additionally, the VITEK COMPACT PRO has received FDA clearance, reflecting its status as an updated identification and AST platform with enhanced performance capabilities.
• bioMérieux (France) launched its automated microbiology middleware, MAESTRI,A in early 2023, streamlining lab workflows and enhancing accuracy in AST data management
BD
• Enhanced its Phoenix™ M50 automated ID/AST system with new regulatory approvals. Encountered supply chain issues in blood culture media, affecting some clinical laboratories.
• BD (Becton, Dickinson & Co.) furthered its collaboration with Accelerate Diagnostics (US) by integrating Accelerate’s rapid testing platforms into its global offering, cutting susceptibility result times from days to hours.

Buy now the latest version of this report: https://www.futurewiseresearch.com/checkout.aspx?ReportId=7885&license=multi

**Objectives of this Study: **
1. To provide a comprehensive analysis of the Antimicrobial Susceptibility By Product, By Method, By Type, By Application, By End User and By Region.
2. To offer detailed insights into factors such as drivers, restraints, trends, and opportunities, as well as segmental and regional influences on market growth.
3. To evaluate current market trends and forecast micro-markets, presenting overall market projections in the form of data sets and PowerPoint presentations.
4. To predict the market size in key regions, including North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of contents as per your requirement
• The customization services offered are free of charge with the purchase of any license of the report.
• You can directly share your requirements/changes to the current table of contents to: [email protected]

FutureWise Research
Contact Person: Vinay Thaploo.
Email: [email protected]
Contact Number: Asia: +91 8605575209 | UK: +44 0113 519 7222
Website: www.futurewiseresearch.com